The world's scientific and social network for malaria professionals
Subscribe to free Newsletter | 11151 malaria professionals are enjoying the free benefits of MalariaWorld today


Risk factors for the accuracy of the initial diagnosis of malaria cases in China: a decision-tree modelling approach

January 22, 2022 - 20:43 -- Open Access
Gang Li, Donglan Zhang, Zhuo Chen, Da Feng, Xinyan Cai, Xiaoyu Chen, Shangfeng Tang and Zhanchun Feng
Malaria Journal 2022 21:11, 7 January 2022

Early accurate diagnosis and risk assessment for malaria are crucial for improving patients’ terminal prognosis and preventing them from progressing to a severe or critical stage. This study aims to describe the accuracy of the initial diagnosis of malaria cases with different characteristics and the factors that affect the accuracy in the context of the agenda for a world free of malaria.

Prediction of the CYP2D6 enzymatic activity based on investigating of the CYP2D6 genotypes around the vivax malaria patients in Yunnan Province, China

December 17, 2021 - 21:18 -- Open Access
Ying Dong, Herong Huang, Yan Deng, Yanchun Xu, Mengni Chen, Yan Liu and Canglin Zhang
Malaria Journal 2021 20:448, 25 November 2021

In recent years, the incidence rate of vivax malaria recurrence still had 3.1% in Yunnan Province population after eradication therapy using primaquine (PQ). In order to understand the specific failure reasons for preventing vivax malaria relapses, a preliminary exploration on the CYP2D6 enzyme activity was carried out in the vivax malaria patients in Yunnan Province population by analysing mutational polymorphism in the coding region of CYP2D6 gene.

Achieving malaria elimination in China

December 11, 2021 - 21:43 -- Open Access
Cao J, Newby G, Cotter C, Hsiang MS, Larson E, Tatarsky A, Gosling RD, Xia Z, Gao Q
Lancet Public Health. 2021 Dec;6(12):e871-e872

China was certified malaria-free by WHO on June 30, 2021, a remarkable achievement and the culmination of decades of dedicated effort by the national malaria programme and its partners.

Genetic diversity and immunogenicity of the merozoite surface protein 1 C-terminal 19-kDa fragment of Plasmodium ovale imported from Africa into China

December 1, 2021 - 20:25 -- Open Access
Xu Q, Liu S, Kassegne K, Yang B, Lu J, Sun Y, Zhong W, Zhang M, Liu Y, Zhu G, Cao J, Cheng Y
Parasit Vectors. 2021 Nov 24;14(1):583

Merozoite surface protein 1 (MSP1) plays an essential role in erythrocyte invasion by malaria parasites. The C-terminal 19-kDa region of MSP1 has long been considered one of the major candidate antigens for a malaria blood-stage vaccine against Plasmodium falciparum. However, there is limited information on the C-terminal 19-kDa region of Plasmodium ovale MSP1 (PoMSP119). This study aims to analyze the genetic diversity and immunogenicity of PoMSP119.

Intensive surveillance, rapid response and border collaboration for malaria elimination: China Yunnan’s ‘‘3 + 1’’strategy

October 23, 2021 - 18:31 -- Open Access
Jian-Wei Xu, Zu-Rui Lin, Hong-Ning Zhou, et al.
Malaria Journal 2021 20:396, 9 October 2021

Eliminating malaria and preventing re-establishment of malaria transmission in border areas requires universal coverage of malaria surveillance and a rapid response to any threats (i.e. malaria cues) of re-establishing transmission.

Care-seeking delay of imported malaria to China: Implications for improving post-travel healthcare for migrant workers

October 2, 2021 - 13:08 -- Open Access
Lu G, Cao Y, Chen Q, Zhu G, Müller O, Cao J
J Travel Med. 2021 Sep 28:taab156

Imported malaria cases continue to pose major challenges in China as well as in other countries having achieved elimination. Our study aims to identify the factors influencing the timing of care-seeking after symptom onset among migrant workers with imported malaria, in order to develop innovative interventions to improve access and provision of post-travel healthcare for returning migrants.

Epidemiological characterization of imported recurrent Plasmodium vivax and Plasmodium ovale in China, 2013-2020

August 25, 2021 - 16:59 -- Open Access
Cui Y, Zhang L, Xia Z, Zhou H, Huang F
Infect Dis Poverty. 2021 Aug 23;10(1):113

China has reached important milestones in the elimination of malaria. However, the numbers of imported recurrent cases of Plasmodium vivax and P. ovale are gradually increasing, which increases the risk of malaria re-establishment in locations where Anopheles mosquitoes exist. The aim of this study is to characterize the epidemiological profiles of imported recurrent P. vivax and P. ovale cases, quantifying the recurrence burden and guiding the development of appropriate public health intervention strategies.

Limited polymorphism in k13 gene of Plasmodium falciparum and k12 of Plasmodium vivax isolates imported from African and Asian countries between 2014 and 2019 in Hangzhou city, China

August 25, 2021 - 16:57 -- Open Access
Jin X, Zhu S, Xu W, Chen J, Ruan W, Wang X
BMC Infect Dis. 2021 Aug 21;21(1):853

Malaria causes major public health problems globally and drug resistance hinders its control and elimination. Molecular markers associated with drug resistance are considered as a beneficial tool to monitor the disease trends, evolution and distribution so as to help improve drug policy.

Malaria: elimination tale from Yunnan Province of China and new challenges for reintroduction

July 28, 2021 - 13:57 -- Open Access
Yang HL, Baloch Z, Zhou HN, et al.
Infect Dis Poverty. 2021 Jul 21;10(1):101

Eradication of infectious disease is the sanctified public health and sustainable development goal around the world.

The mechanisms of action of Plasmodium infection against cancer

July 14, 2021 - 10:30 -- Open Access
Chen X, Qin L, Hu W, Adah D
Cell Commun Signal. 2021 Jul 9;19(1):74

Our murine cancer model studies have demonstrated that Plasmodium infection activates the immune system that has been inhibited by cancer cells, counteracts tumor immunosuppressive microenvironment, inhibits tumor angiogenesis, inhibits tumor growth and metastasis, and prolongs the survival time of tumor-bearing mice. Based on these studies, three clinical trials of Plasmodium immunotherapy for advanced cancers have been approved and are ongoing in China.


Subscribe to RSS - China